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Immunoglobulin G (IgG) fragment crystallizable (Fc) N-glycosylation has a large influence 
on the affinity of the antibody for binding to Fcγ-receptors (FcγRs) and C1q protein, 
thereby influencing immune effector functions. IgG Fc glycosylation is known to be 
partly regulated by genetics and partly by stimuli in the microenvironment of the B cell. 
Following allogeneic hematopoietic stem cell transplantation (HSCT), and in the pres-
ence of (almost) complete donor chimerism, IgG is expected to be produced by, and 
glycosylated in, B cells of donor origin. We investigated to what extent IgG glycosylation 
in patients after transplantation is determined by factors of the donor (genetics) or the 
recipient (environment). Using an IgG subclass-specific liquid chromatography–mass 
spectrometry method, we analyzed the plasma/serum IgG Fc glycosylation profiles of 
34 pediatric patients pre-HSCT and at 6 and 12 months post-HSCT and compared 
these to the profiles of their donors and age-matched healthy controls. Patients treated 
for hematological malignancies as well as for non-malignant hematological diseases 
showed after transplantation a lower Fc galactosylation than their donors. Especially for 
the patients treated for leukemia, the post-HSCT Fc glycosylation profiles were more 
similar to the pre-HSCT recipient profiles than to profiles of the donors. Pre-HSCT, 
the leukemia patient group showed as distinctive feature a decrease in sialylation and 
in hybrid-type glycans as compared to healthy controls, which both normalized after 
transplantation. Our data suggest that IgG Fc glycosylation in children after HSCT does 
not directly mimic the donor profile, but is rather determined by persisting environmental 
factors of the host.
Keywords: immunoglobulin g, fragment crystallizable glycosylation, N-glycan, hematopoietic stem cell 
transplantation, immune reconstitution
inTrODUcTiOn
The N-glycan attached to the conserved glycosylation site of the fragment crystallizable (Fc) region of 
immunoglobulin G (IgG) has a large influence on the structure and function of the antibody (1, 2). 
The presence or absence of specific monosaccharides have proven to be crucial both in modulating 
the affinity of IgG binding to Fcγ-receptors (FcγRs) and in the activation of the complement system. 
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For example, the absence of a core fucose on the Fc glycan results 
in a 10- to 20-fold increase in binding affinity to the FcγRIIIa and 
FcγRIIIb and a corresponding increase in antibody-dependent 
cellular cytotoxicity (2, 3). For IgG Fc binding to complement 
factor C1q, galactosylation plays a primary role and is associated 
positively with binding affinity and downstream complement-
dependent cytotoxicity (CDC) (3, 4).
Besides the functional implications of altered IgG Fc glycosyla-
tion described above, the IgG Fc glycosylation profile was found 
to be associated with altered physiological states and disease activ-
ity. For example, galactosylation decreases with age in the adult 
population (5). In children, on the other hand, Fc galactosylation 
remains relatively constant with age, while bisection increases 
and fucosylation and sialylation decrease (6). Furthermore, in 
adults, total IgG-Fc galactosylation is decreased in rheumatoid 
arthritis and active tuberculosis infections (7, 8), but also in dif-
ferent types of cancer, like ovarian cancer and colorectal cancer 
(9, 10). Antigen-specific IgG antibodies may display discrimina-
tive glycosylation patterns. For example, gp120-specific antibod-
ies in HIV-infected patients show a decrease in fucosylation as 
compared to the total pool of IgG in these patients (11).
Immunoglobulin G Fc N-glycans are co-translationally 
attached to the protein in the endoplasmic reticulum (ER) of B 
lymphocytes and enzymatically shaped into their final structure 
in the ER and Golgi apparatus. This process is dependent on the 
time the protein spends in the Golgi apparatus, the abundance 
of monosaccharide donors and presence of specific glycosyl-
transferases and glycosidases, adding and removing particular 
monosaccharides to and from the glycoconjugates, respectively 
(12). All these factors are known to be partly regulated by the 
genetics of the B cell (13, 14), and on the other hand, by external 
stimuli in the microenvironment of the cells, like hormones and 
cytokines (15, 16). For example, in in vitro experiments, all-trans 
retinoic acid and human interleukin (IL)-21 cause a decrease 
and increase in both IgG1 Fc galactosylation and sialylation, 
respectively (16). However, the exact mechanisms leading to 
specific IgG Fc glycosylation profiles are not fully understood yet. 
Unraveling the up-stream factors influencing IgG glycosylation 
will improve the understanding of changes hereof that are associ-
ated with immune-related diseases.
Allogeneic hematopoietic stem cell transplantation (HSCT) 
is a curative treatment for patients with malignant as well as 
non-malignant immune-hematological diseases. In addition to 
the cure of the primary disease, proper immune reconstitution 
is an important goal of any HSCT procedure. Previous studies 
in non-transplant patients have demonstrated that IgG Fc glyco-
sylation patterns are strongly influenced by both B cell intrinsic 
and (host) environmental factors (13, 15, 16). HSCT provides 
a unique setting to study the impact of both determinants on 
IgG Fc glycosylation in transplanted patients. With this aim, we 
studied a group of pediatric patients that were successfully treated 
for their initial disease, and in whom (close to) complete donor 
chimerism was documented at 6 and 12 months post-transplant. 
Furthermore, the patient group was homogeneous in terms of 
reaching steady state within this timeframe, i.e., the presence of 
an uncomplicated clinical condition without requirement of any 
immunomodulatory medication.
The IgG Fc glycosylation profiles of transplant recipients were 
analyzed before and after HSCT and compared to the profiles of 
the donors as well as to those of age-matched healthy controls.
MaTerials anD MeThODs
hscT Patients
In the period 2010–2014, 211 allogeneic HSCT procedures were 
performed in children at the pediatric transplantation unit of the 
LUMC. Criteria for exclusion of patients to enroll in the current 
study were: death within 1 year after HSCT, an eventful course 
in the first year after HSCT such as relapse of the original dis-
ease, acute graft-vs.-host disease (GvHD) grade >1 or extensive 
chronic GvHD, dependency of IgG supplementation within a 
period of 2 months before taking a serum or plasma sample at 6 
and 12 months after HSCT and dependency of immunosuppres-
sive drugs (i.e., cyclosporine A) at 7 months after HSCT (median 
3.8  months). In addition, patients treated for thalassemia and 
with a persistent mixed chimerism in peripheral blood mono-
nuclear cells (PBMC) defined as <85% donor origin at 1-year 
post-HSCT were excluded. Finally, to be included in the study, 
at least three of the four following serum or plasma samples of 
a donor-recipient pair should be available: from the graft donor, 
from the patient before HSCT (and start of the conditioning), and 
at 6 and 12 months after HSCT.
The final study cohort consisted of 34 pediatric HSCT recipi-
ents. In Table  1, the characteristics of these patients and their 
donors are summarized. All transplantation procedures were 
performed according to national protocols and in line with the 
recommendations of the European group for Blood and Marrow 
Transplantation.
sampling and study approval
Serum or plasma samples of HSCT recipients were collected 
between 6 and 28 days (median 13 days) prior to HSCT, i.e., before 
start of conditioning, and 6  months (range 158–205  days) and 
12 months (range 313–499 days) after HSCT. From 29 of the stem 
cell donors (excluding umbilical cord donors) a plasma or serum 
sample was collected between 0 and 159 days (median 14 days) 
before donation of the graft (Table 1). All clinical samples were 
collected with approval of the Medical Ethics Committee of the 
LUMC, Leiden (project P01.028) and after receiving written 
informed consent from the participants. In addition, samples 
were collected from 81 healthy controls in the same age range 
as the patients. The healthy control samples were collected with 
approval of the Medical Ethics Committee of the Erasmus MC, 
Rotterdam (MEC-2005-137) and after receiving written informed 
consent from the participants (6, 17).
igg glycopeptide analysis and Data 
Processing
All 135 clinical samples (patients and donors) were randomized 
in 96-well plates, together with 12 plasma standards (VisuCon 
pooled plasma; Affinity Biologicals Inc., Ancaster, ON, Canada) 
and 5 PBS blanks. Healthy control samples were randomized on 
separate plates, including 29 plasma standards and 8 PBS blanks. 
Table 1 | Summary of the cohort.
Patients
group Malignant hDa non-malignant hDa Total
Number (N) of patients 16 18 34
Age at HSCTb (median, range) 9.4 (0.8–17.8) 5.7 (0.7–14.9) 7.5 (0.7–17.8)
Sex recipient (% female) 31.3 16.7 23.5
Donor type: 
IRD (BM/CB) 4 (4/0) 11 (10/1) 15 (14/1)
MUD (BM/CB) 10 (9/1) 6 (3/3) 16 (12/4)
ORD (PBSC) 2 (2) 1 (1) 3 (3)
Donor ageb (median, range) 26.6 (8.9–49.0) 17.1 (2.8–47.5) 25.6 (2.8–49.0)
Sex donor (% female) 12.5 35.7 24.1
Graft: undepl. (N)/CD34-enriched (N) 14/2 17/1 31/3
% chimerismc (median, range) 100 (98–100) 100 (87–100) 100 (87–100)
Acute GvHD (grade 1, N) 2 1 3
Chronic GvHD (limited, N) 1 0 1
1st sample (N) 16 16 32
1st sampled (median, range) −13 (−21 to −6) −14 (−28 to −6) −13 (−28 to −6)
2nd sample (N) 16 18 34
2nd sampled (median, range) 176 (162–199) 183 (158–205) 182 (158–205)
3rd sample (N) 16 18 34
3rd sampled (median, range) 375 (348–499) 365 (313–431) 372 (313–499)
Donor sample (N) 15 14 29
Donor sampled (median, range) −1 (−159 to 0) −24 (−43 to 0) −14 (−159 to 0)
controls
group age matched to malignant hD age matched to non-malignant hD Total
Controls (N) 16 18 81
Age (median, range) 9.3 (0.8–16.8) 6.0 (0.6–13.8) 6.2 (0.5–16.8)
Sex (% female) 68.8 27.8 49.4
aHD, hematological disease; malignant HD: acute lymphoblastic leukemia: N = 10; myelodysplastic syndrome/acute myeloblastic leukemia: N = 2; acute myeloblastic leukemia: 
N = 4. Non-malignant HD: thalassemia: N = 4, Fanconi anemia: N = 3, sickle cell disease: N = 2, severe aplastic anemia: N = 1, progressive bone marrow failure: N = 1, 
neutropenia congenita: N = 1, Glanzmann thrombasthenia: N = 1, hemophagocytic lymphohistiocytosis: N = 4, X-linked lymphoproliferative disease: N = 1.
bAge at hematological stem cell transplantation and graft donation (excluding cord blood donors), respectively, in years.
c% donor chimerism in peripheral blood mononuclear cells (PBMC) at 1-year post-HSCT.
dDay of serum/plasma sampling relative to the day of HSCT.
IRD, identical related donor; MUD, matched unrelated donor; ORD, other than HLA-genotypically identical related donor; BM, bone marrow;  
CB, cord blood; PBSC, peripheral blood stem cells; GvHD, graft-vs.-host disease.
FigUre 1 | Glycan structures found on immunoglobulin G (IgG)-fragment 
crystallizable (Fc). Both hybrid-type and diantennary complex-type glycan 
structures were found on the IgG Fc glycopeptides in our study. Hybrid-type 
glycans varied by the presence of a sialic acid and/or a bisecting  
N-acetylglucosamine (GlcNAc). Diantennary complex-type glycans were 
found with zero to two galactoses, zero to two sialic acids, and the presence 
or absence of a bisecting GlcNAc and/or a core fucose. Monosaccharide 
linkages were based on literature (6, 13, 20, 21). Green circle: mannose, 
yellow circle: galactose, blue square: GlcNAc, red triangle: fucose, pink 
diamond: N-acetylneuraminic acid (Neu5Ac/sialic acid).
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IgG was isolated using Protein G affinity beads (GE Healthcare, 
Uppsala, Sweden) and digested by trypsin as described before 
(18), see Supplementary Materials and Methods in Supplementary 
Material. The IgG digest was separated and analyzed by nano-
liquid chromatography (LC) coupled by electrospray ionization 
to a Maxis Impact HD quadrupole time-of-flight mass spec-
trometer (q-TOF-MS; Bruker Daltonics, Bremen, Germany) as 
described before (18), see Supplementary Materials and Methods 
in Supplementary Material. Prior to statistical analysis, raw LC–
MS data were extracted and curated using the in-house developed 
software LacyTools v0.0.7.2 as described previously (18, 19); for 
all cohort-specific extraction parameters see Supplementary 
Materials and Methods in Supplementary Material.
statistics
The absolute intensities of the extracted glycoforms (Figures 1 
and 2; Table S1 in Supplementary Material) were total-area 
normalized per IgG subclass and levels of galactosylation, 
sialylation, fucosylation, as well as other derived traits were 
calculated (Table  2; Table S2 in Supplementary Material). To 
assess data quality throughout the cohort measurements, the 
plasma standards were analyzed, revealing highly repeatable 
glycosylation profiles for all subclasses, with median relative SD 
of all extracted glycoforms of IgG1, IgG2/3, and IgG4 being 3.4, 
2.7, and 2.1%, respectively (Figure S1 in Supplementary Material). 
Table 2 | Subclass-specific-derived traits.
Derived traita Depictionb Descriptionc
Hybrids Fraction of hybrid-type glycans
Bisection Fraction of glycans with a bisecting 
N-acetylhexosamine
Fucosylation Fraction of glycans with a core fucose
Galactosylation Galactosylation per antenna of 
diantennary glycans
Sialylation Sialylation per antenna of diantennary 
glycans
Sialylation per 
galactose
Sialylation per galactose of diantennary 
glycans
aThe individual glycoforms were grouped based on their glycosylation features as 
described before for immunoglobulin G glycopeptides in human (6).
bGreen circle: mannose, yellow circle: galactose, blue square: N-acetylglucosamine, 
red triangle: fucose, pink diamond: N-acetylneuraminic acid. The depictions of the 
derived traits show the minimally required composition to contribute to a trait.
cFor detailed calculations of the traits, see Table S2 in Supplementary Material.
FigUre 2 | Representative mass spectra of IgG1 glycopeptides. Annotated are the 15 most abundant IgG1 glycoforms detected for a 7.5 years old, male, acute 
myeloid leukemia patient (a) before hematopoietic stem cell transplantation (HSCT), (b) 12 months after HSCT and (c) his 24 years old, healthy, male donor. Triply 
charged glycopeptides are shown, the proposed glycan structures are based on literature (6, 13, 20, 21). Green circle: mannose, yellow circle: galactose, blue 
square: N-acetylglucosamine (GlcNAc), red triangle: fucose, pink diamond: N-acetylneuraminic acid (Neu5Ac). Differences in relative abundances of glycoforms as 
compared to the patient pre-HSCT are indicated by red (lower than in pre-HSCT patient) and blue (higher than in pre-HSCT patient) arrows.
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For three patients, both plasma and serum samples, obtained at 
corresponding time points, were available. Comparison of these 
samples showed similar IgG Fc glycosylation profiles for both 
materials (Figure S2 in Supplementary Material). The difference 
between measurements in plasma and serum from the same 
patient was lower than the variation between patients, enabling 
the use of both materials in this study.
Further statistical analysis and data visualization were per-
formed using R 3.1.2 (R Foundation for Statistical Computing, 
Vienna, Austria) and RStudio 0.98.1091 (RStudio, Inc., Boston, 
MA, USA). Patients pre- and 12 months post-HSCT, as well as 
patients and donors, were compared with two-sided Wilcoxon 
signed-rank tests. Healthy controls and patients were compared 
with two-sided Mann–Whitney U tests. The samples of the patients 
taken 6 months post-HSCT were left out of the statistical analysis 
to reduce the data density, but were shown in some figures to 
illustrate the dynamics of IgG Fc glycosylation profiles after HSCT. 
Statistical tests were performed for the whole dataset, as well as 
after stratification on diagnosis: non-malignant hematological 
disease and malignant hematological disease (Table 1). For the 
tests after stratification for diagnosis, subgroups of one-to-one 
age-matched healthy controls were used. A significance threshold 
FigUre 3 | Immunoglobulin G (IgG) fragment crystallizable (Fc) galactosylation in all patients, compared to their donors and age-matched healthy controls. IgG Fc 
galactosylation on (a) IgG1, (b) IgG2/3, and (c) IgG4 is different between patients before hematopoietic stem cell transplantation (HSCT) (Pre) and their donors (D). 
No changes were observed between patients pre- and 12 months post-HSCT (12 m). In general, patients before and after HSCT have lower galactosylation than 
age-matched healthy controls (H), although this was not statistically significant for IgG4 galactosylation. 6 m: patients 6 months after HSCT. Patients and donors 
were compared by Wilcoxon signed-rank tests, healthy controls and patients with Mann–Whitney U tests. p-Values <0.015 were considered statistically significant 
after 5% FDR correction (as indicated by the asterisks above the plots). For IgG1 galactosylation, n (H, Pre, 6 m, 12 m, D) = 81, 32, 34, 34, 29, for IgG2/3 
galactosylation, n (H, Pre, 6 m, 12 m, D) = 69, 32, 32, 33, 29, for IgG4 galactosylation, and n (H, Pre, 6 m, 12 m, D) = 59, 27, 15, 17, 28, respectively.
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(α) = 0.015 was used throughout the study after correcting for 
multiple testing using the Benjamini–Hochberg approach with 
an FDR of 5%.
resUlTs
The IgG Fc glycosylation profiles of 34 pediatric HSCT patients 
were followed over time, starting with a sample prior to the HSCT 
and followed by two longitudinal samples, 6 and 12 months post-
HSCT. In addition, the IgG Fc glycosylation of the donors prior 
to the donation of the grafts and of age-matched healthy controls 
was assessed (Table 1). IgG Fc glycopeptides were analyzed by 
LC–MS, which enabled the detection of 22 glycoforms on IgG1, 
16 on IgG2/3, and 11 on IgG4 (Figures  1 and 2; Table S1 in 
Supplementary Material). Furthermore, derived glycosylation 
traits, such as levels of galactosylation, sialylation, fucosylation, 
and bisection were calculated (Table 2; Table S2 in Supplementary 
Material).
igg Fc glycosylation Differences between 
Patients and healthy controls
For the total patient group pre-HSCT, IgG Fc bisection was higher 
than for healthy controls (e.g., IgG1: 14.8 vs. 10.1%, respectively, 
p = 2.5*10−7; Table S3 and Figure S3 in Supplementary Material), 
while IgG1 and IgG2/3 galactosylation and sialylation were lower 
(e.g., IgG1 galactosylation: 51.9 vs. 59.9%, p = 3.2*10−6; Figure 3; 
Table S3 and Figure S3 in Supplementary Material). Furthermore, 
specifically on IgG1, fucosylation and hybrid-type glycans were 
lower in patients than in controls (fucosylation: 95.6 vs. 97.5%, 
p = 1.1*10−5, and hybrid-types: 0.3 vs. 0.4%, p = 6.6*10−3; Table 
S3 and Figure S3 in Supplementary Material).
The patients were grouped according to their diagnosis, 
resulting in a group with malignant and with non-malignant 
hematological diseases (Table 1). These groups differ in disease 
course and treatment before HSCT, and were hence compared 
separately to healthy controls with respect to IgG Fc glycosyla-
tion (Tables S4 and S5 in Supplementary Material). The pre-
HSCT malignant hematological disease group differed in IgG 
Fc glycosylation from age-matched healthy controls similar to 
the overall pre-HSCT patient group (Figures 4 and 5; Table S4 
in Supplementary Material). In contrast, the pre-HSCT non-
malignant hematological disease group only showed a decrease 
in IgG1 fucosylation as compared to age-matched healthy con-
trols (Table S5 and Figure S5 in Supplementary Material).
The impact of hscT on igg Fc 
glycosylation
In the whole dataset, pre-HSCT IgG Fc glycosylation differed 
from the corresponding donors (Table S3 and Figure S3 in 
Supplementary Material). For all subclasses, IgG galactosylation 
was higher in donors than in recipients pre-HSCT (IgG1: 60.8 
vs. 51.9%, p = 5.5*10−6; Figure 3). In addition, IgG1 fucosylation 
was lower in donors (94.1%) than in recipients pre-HSCT (95.6%, 
p = 1.0*10−3), while IgG1 sialylation was higher in donors (10.0%) 
than in recipients (8.5%, p =  1.5*10−3; Table S3 and Figure S3 
in Supplementary Material). Both galactosylation and IgG1 
sialylation were still lower in patients 12 months post-HSCT as 
compared to the donors, and no difference in galactosylation 
and sialylation was observed between the patients pre-HSCT 
and 12 months post-HSCT (Figure 3; Table S3 and Figure S3 in 
Supplementary Material). The differences in IgG Fc glycosylation 
between pre-HSCT patients and healthy controls, as described 
FigUre 5 | IgG1 fragment crystallizable (Fc) glycosylation features in patients with malignant hematological diseases, compared to their donors and age-matched 
healthy controls. IgG1 (a) hybrid-type glycans and (b) sialylation differ between healthy controls (H) and patients before hematopoietic stem cell transplantation 
(HSCT) (Pre). In addition, IgG1 (a) hybrid-type glycans and (b) sialylation are different between patients and donors (D), and IgG1 (a) hybrid-type glycans and (c) 
sialylation per galactose change within the patients after HSCT. 6 m: patients 6 months after HSCT, 12 m: patients 12 months after HSCT. Patients and donors were 
compared by Wilcoxon signed-rank tests, healthy controls and patients with Mann–Whitney U tests. p-Values <0.015 were considered statistically significant after 
5% FDR correction (as indicated by the asterisks above the plots). For all IgG1 glycosylation features in patients treated for malignant hematological diseases, n (H, 
Pre, 6 m, 12 m, D) = 16, 16, 16, 16, 15, respectively.
FigUre 4 | IgG1 fragment crystallizable (Fc) galactosylation in all patients 
stratified on diagnose, compared to their donors and age-matched healthy 
controls. IgG1 Fc galactosylation in children (a) with non-malignant 
hematological diseases and (b) with malignant hematological diseases. H: 
age-matched healthy controls, Pre: patients prior to hematopoietic stem cell 
transplantation (HSCT), 6 m: patients 6 months after HSCT, 12 m: patients 
12 months after HSCT, D: donors prior to HSCT. Patients and donors were 
compared by Wilcoxon signed-rank tests, healthy controls and patients with 
Mann–Whitney U tests. p-Values <0.015 were considered statistically 
significant after 5% FDR correction (as indicated by the asterisks above the 
plots). For non-malignant hematological diseases, n (H, Pre, 6 m, 12 m, 
D) = 18, 16, 18, 18, 14, for malignant hematological diseases, n (H, Pre, 6 m, 
12 m, D) = 16, 16, 16, 16, 15, respectively.
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above, were still observed 12 months post-HSCT, except for IgG1 
hybrid-type glycans and IgG2/3 sialylation which both normal-
ized (Table S3 in Supplementary Material).
The effect of HSCT on IgG Fc glycosylation was studied 
additionally for the two diagnosis groups separately (Tables S4 
and S5 and Figures S4 and S5 in Supplementary Material). The 
observations made on IgG Fc galactosylation in the total dataset, 
were found back in the patients treated for malignant hematologi-
cal diseases, but only partly in the other subgroup (Figure 4). For 
the patients treated for hematological malignancies, galactosyla-
tion was lower for the recipients pre-HSCT (46.3%) than for the 
donors (IgG1: 61.0%, p = 1.2*10−4). The reduced galactosylation 
in recipients was still observed 12  months post-HSCT (47.4%, 
p = 6.1*10−5), while no difference was observed between patients 
before and after HSCT (Figure  4; Table S4 in Supplementary 
Material). Another glycosylation trait that was found to be over-
all low, but significantly lower only in pre-HSCT patients with 
a hematological malignancy as compared to their donors, was 
the relative presence of the IgG1 hybrid-type glycans (recipient: 
0.25% and donor: 0.32%, p = 1.2*10−4). In contrast to galacto-
sylation, the abundance of hybrid-type glycans normalized after 
HSCT (0.35%; Figure 5A; Table S4 in Supplementary Material). 
In addition, IgG1 sialylation was only lower in the patients with 
a hematological malignancy pre-HSCT (6.8%) as compared to 
their donors (9.6%, p =  3.1*10−4), and showed an increasing 
trend after HSCT (Figure 5B). This increase in IgG1 sialylation 
was more pronounced when assessed per galactose (pre-HSCT: 
15.0%, 12 months post-HSCT: 17.6%, p = 1.5*10−3) and sialyla-
tion per galactose was higher after HSCT (17.6%) than in the 
corresponding donors (15.8%, p = 1.2*10−4; Figure 5C).
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The group treated for non-malignant diseases showed no 
differences between donors and recipients pre-HSCT (Figure 4; 
Table S5 in Supplementary Material). However, a decrease in fuco-
sylation was observed after HSCT (IgG1-pre: 96.3%, post: 95.5%, 
p = 1.2*10−2; Table S5 and Figure S5 in Supplementary Material). 
In addition, IgG1 fucosylation and galactosylation were lower 
post-HSCT than for age-matched healthy controls (fucosylation: 
95.5 vs. 97.9%, p = 6.6*10−4, and galactosylation: 51.4 vs. 60.2%, 
p = 6.0*10−6; Figure S5 in Supplementary Material), while bisec-
tion was higher for the post-HSCT patients than compared to 
the controls (13.5 and 10.1%, p = 1.1*10−4, respectively). Of note, 
the post-HSCT levels of galactosylation (IgG1: 51.4%) were also 
lower than those found in the donors (60.8%, p = 9.8*10−4; Figure 
S5 and Table S5 in Supplementary Material).
DiscUssiOn
recipient galactosylation is Different 
From Donor galactosylation
Here, we studied IgG Fc glycosylation in pediatric patients 
before and after HSCT as compared to their donors. Looking 
at the whole dataset, the most prominent IgG Fc glycosylation 
differences between donors and recipients pre-HSCT were 
observed in the galactosylation, which was lower in the patients 
as compared to the donors independently of the IgG subclass. 
This cannot be explained by the age difference between the 
groups, as galactosylation does hardly differ between children 
and young adults (6, 22). Furthermore, a significant difference 
remained present for the galactosylation of IgG1 and IgG2/3 
when comparing recipients pre-HSCT with healthy age-
matched controls. Therefore, a low galactosylation state most 
likely reflects glycosylation changes caused by the disease and/or 
the treatment thereof. This is supported by the observation that, 
when the patients were stratified based on diagnosis, only the 
children treated for hematological malignancies showed a lower 
galactosylation as compared to both their donors and the healthy 
age-matched controls. IgG Fc galactosylation was reported 
before to be lowered in patients with solid tumors (9, 10).
Twelve months after HSCT, the patients treated for hemato-
logical malignancies still showed a lower IgG Fc galactosylation 
as compared to their donors, which indicates that the recipients 
produce IgG with a Fc glycosylation pattern that partly mimics 
the profile of the recipient pre-HSCT and not the donor profile. 
Of note, the patient-subgroup treated for non-malignant hema-
tological diseases did also show a low galactosylation 12 months 
post-HSCT, while their levels did not differ from the donor levels 
at the pre-HSCT timepoint. The low level of galactosylation at 
this stage after HSCT, when all study patients were in a stable 
and uncomplicated clinical condition, was comparable between 
the two subgroups. A likely explanation for this aberrant IgG Fc 
galactosylation is, at least partly, the regulation of this Fc glyco-
sylation trait by host microenvironmental factors like cytokines 
or hormones which persists for a prolonged period after HSCT. 
In this respect, it would be interesting to study the expression of 
glycan-modifying enzymes, like glycosyltransferases and glycosi-
dases, and influences thereof, both before and after HSCT. While 
the used chemotherapeutic medication (for example, clofarabine) 
has been reported to perform their function through epigenetic 
mechanisms, it seems unlikely that this influences the IgG pro-
duction by the donor B cells as these drugs are administered to 
the patients before the HSCT and are cleared from the circulation 
rapidly.
hybrid-Type glycans and sialylation 
increase after hscT
While aberrant galactosylation in patients treated for hemato-
logical malignancies did not change after HSCT, IgG1 hybrid-
type glycans and sialylation per galactose increased to a normal 
level after HSCT in these patients. Although for all samples in 
the cohort the total relative abundance of the hybrid-type glycans 
was below 1% of the total glycan profile, still a clear increase 
was observed in the proportion of hybrid-type glycans after 
HSCT for hematological malignancies. Hybrid-type structures 
are intermediate in the glycosylation biosynthesis, emerging in 
the medial Golgi with limited α-mannosidase II activity to trim 
the mannoses on the α1,6-arm of the glycoconjugate, or upon 
addition of a bisecting GlcNAc before trimming takes place, as 
the presence of bisection inhibits the activity of α-mannosidase 
II (23). Hybrid-type glycans have been reported to be present on 
human polyclonal IgG (24, 25), albeit in minor amounts, and little 
is known about their specific effects on IgG-Fc function.
Similar to galactosylation, IgG1 sialylation was low in 
patients with hematological malignancies pre-HSCT as 
compared to both the healthy controls and donors. However, 
after HSCT, sialylation showed an increase, which was more 
pronounced when studied relative to the level of galactosyla-
tion. While pre-HSCT sialylation was lower than in healthy 
controls and in donors, post-HSCT no difference was observed 
between case and control or donor levels. In addition, post-
HSCT sialylation per galactose was higher than the levels 
observed in the donors. While overall sialylation effects might 
be a possible side-effect of changing galactosylation (terminal 
galactoses are a substrate for sialylation), an increase in the 
amount of sialic acids per galactose is likely to be caused by the 
upregulation of the sialyltransferase ST6Gal1 or an increased 
availability of the substrate CMP-sialic acid (12). Next to 
the regulation inside the B  cell by genetic and local factors 
(13, 15, 16), IgG Fc sialylation in mice is also reported to be 
dynamically regulated independently of the B cell (26). This is 
suggested to happen in a stress-driven way, with the accumula-
tion of platelets that serve as source of CMP-sialic acid (27). In 
murine models, an increase in Fc sialylation was reported to 
act as an anti-inflammatory regulator resulting in upregulation 
of the FcγRIIb on macrophages (28). However, this finding is 
hard to translate directly to the human situation, due to the 
differences between mice and men in IgG effector functions 
(29). In human in vitro models, an increased Fc sialylation on 
polyclonal IgG was connected to a decreased C1q binding and, 
consequently, to an impairment of CDC (4).
While various association studies in humans point toward a 
more pronounced role of galactosylation rather than of sialylation 
in potentially mediating pro- and anti-inflammatory effects of 
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IgG (30–32), these studies were all performed in the adult popu-
lation, while knowledge about the effects in children is limited. 
A recent study showed the decrease of sialylation per galactose, 
but not of galactosylation, with age in healthy children (6). 
Contrary, for healthy adults it was reported that galactosylation 
decreases with age, while sialylation per galactose remains stable 
in males and only slightly decreases in females (5). These dif-
ferences in the regulation of IgG galactosylation and sialylation 
between children and adults warrant further investigation as to 
the causes as well as downstream effects.
Both IgG1 hybrid-type glycans and sialylation showed a dif-
ference between the healthy controls or donors and the recipient 
treated for hematological malignancies pre-HSCT which was not 
observed anymore post-HSCT. This might indicate that environ-
mental factors regulating these Fc glycosylation traits have been 
normalized.
Disease-specific igg Fc glycosylation
While for patients treated for hematological malignancies, pre-
HSCT, multiple differences in IgG Fc glycosylation were observed 
as compared to healthy controls, for the group with non-malig-
nant diseases, less profound differences were found between cases 
and controls. Specifically, lower levels of galactosylation and 
sialylation, as well as lower hybrid-type glycans, were exclusively 
observed in the group of hematological malignancies. It has 
previously been reported that IgG galactosylation decreased with 
different forms of cancer in adults, like ovarian and colorectal 
cancer (9, 10), while corresponding knowledge on malignancies 
in children has hitherto been lacking. To our knowledge, the only 
IgG glycosylation studies performed in diseased children so far 
were in patients with allergic diseases, asthma, and juvenile idi-
opathic arthritis, showing no associations between aberrant IgG 
glycosylation profiles and the two former disorders (33, 34), and 
a decreased galactosylation and sialylation in juvenile idiopathic 
arthritis (35). Here, we show that pediatric patients treated for 
hematological malignancies have an altered IgG Fc glycosylation, 
which might be specific for their condition or treatment regimens 
as compared to patients treated for non-malignant hematological 
diseases.
conclusion
While the B cells in children after HSCT are mainly of donor ori-
gin (36) and patients were investigated after reaching independ-
ency of IgG supplementation, we found that IgG Fc glycosylation 
in our pediatric cohort did not reflect the glycosylation pattern 
of the donors. Galactosylation was already low pre-HSCT in 
patients treated for hematological malignancies as compared to 
their donors and age-matched healthy controls, and remained at 
this lower level the first year after HSCT. In patients treated for 
non-malignant hematological diseases, galactosylation showed 
a strong decrease to similarly low levels after HSCT. These data 
suggest that external local influences on the IgG Fc glycosylation 
are operative before HSCT in patients treated for hematological 
malignancies as well long-term after HSCT independently of the 
original disease. To further identify the external factors influenc-
ing IgG glycosylation after HSCT, future research should focus 
on the expression of glycan-modifying enzymes in the ER and 
Golgi apparatus, and in addition on the molecules that can influ-
ence up- and down-regulation of these enzymes, like cytokines 
and hormones (15, 16). Furthermore, antigen-specific IgG gly-
cosylation analysis, for example, of anti-pneumococcal or anti-
meningococcal antibodies after vaccination or of autoantibodies, 
might shed light on the influence of antigen stimulation on the 
IgG glycosylation profile.
Other IgG1 glycosylation features like hybrid-type glycans 
and sialylation were also low prior to HSCT in the group 
treated for hematological malignancies, but normalized after 
transplantation. This could either be explained by normaliza-
tion of environmental factors influencing the latter IgG Fc 
glycosylation traits upon curing the disease or by a reflection of 
the donor glycosylation status based on donor genetics. Future 
studies, in populations that contain both cases with and without 
post-HSCT complications like immunodeficiencies or antibody 
mediated autoimmunity, might reveal pathology-specific glyco-
sylation profiles.
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